Cadrenal Therapeutics (CVKD) Change in Cash (2022 - 2026)

Cadrenal Therapeutics has reported Change in Cash for 5 years, with the latest figure at -$1.7 million in Q1 2026.

• Quarterly Change in Cash rose 36.62% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 753.27% YoY) and the FY2025 annual result came in at -$6.0 million, down 472.04% from the prior year.
• Change in Cash declined to -$1.7 million in Q1 2026 per CVKD's latest filing, from $147707.0 in the prior quarter.
• Over five years, Change in Cash peaked at $5.9 million in Q3 2023 and troughed at -$2.7 million in Q1 2025.
• A 5-year average of $135772.8 and a median of -$673274.0 in 2024 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 13436.33% in 2023, down 902.82% in 2023.
• Over 5 years, Change in Cash stood at -$70496.0 in 2022, then plunged by 902.82% to -$706945.0 in 2023, then jumped by 899.79% to $5.7 million in 2024, then plunged by 97.39% to $147707.0 in 2025, then tumbled by 1250.69% to -$1.7 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$1.7 million, $147707.0, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.